"rationale","instanceType","id","versionIdentifier","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1","2","c680b5b1-cfc1-48e2-ab93-099a9a176835"
